Mitochondrial SPM Synthesis Platform Engineering

Backfill, Etl V1

ID: h-13bbfdc5

Hypothesis

Mitochondrial SPM Synthesis Platform Engineering

Mitochondrial SPM Synthesis Platform Engineering starts from the claim that modulating ALOX5 within the disease context of neurodegeneration can redirect a disease-relevant process.

🧬 ALOX5🩺 neurodegeneration🎯 Composite 65%💱 $0.53▼26.5%debated

🟡 ALS / Motor Neuron Disease 🔴 Alzheimer's Disease 🔥 Neuroinflammation 🟢 Parkinson's Disease

EvidencePending (0%)📖 22 cit🗣 2 debates✓ 12 support✗ 5 oppose

✓ All Quality Gates Passed

🏆 ChallengeSolve: Mitochondrial transfer between astrocytes and neurons$209K →

☰ Compare ⚔️ Duel ⚛️ Collide

📄 Export LaTeX

arXiv Preprint NeurIPS Nature Methods PLOS ONE

📖 Export BibTeXinteract with this hypothesis

Composite65%

🧪 Overview

Mechanistic Overview

Mitochondrial SPM Synthesis Platform Engineering starts from the claim that modulating ALOX5 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "Molecular Mechanism and Rationale The engineered mitochondrial specialized pro-resolving mediator (SPM) synthesis platform represents a paradigm shift in addressing chronic neuroinflammation through targeted delivery of cellular organelles capable of sustained lipid mediator production. The core mechanism centers on the genetic modification of isolated mitochondria to overexpress key enzymes in the SPM biosynthetic pathway, particularly targeting ALOX5 (5-lipoxygenase) and its associated enzymatic cascade. ALOX5 catalyzes the initial oxygenation of arachidonic acid to 5-HPETE (5-hydroperoxyeicosatetraenoic acid), which serves as the precursor for leukotriene synthesis under inflammatory conditions or, critically, for SPM production when coupled with appropriate downstream enzymes. The engineered system incorporates multiple components of the SPM biosynthetic machinery directly into the mitochondrial matrix and inner membrane.

...

Mechanistic Overview

Mitochondrial SPM Synthesis Platform Engineering starts from the claim that modulating ALOX5 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "Molecular Mechanism and Rationale The engineered mitochondrial specialized pro-resolving mediator (SPM) synthesis platform represents a paradigm shift in addressing chronic neuroinflammation through targeted delivery of cellular organelles capable of sustained lipid mediator production. The core mechanism centers on the genetic modification of isolated mitochondria to overexpress key enzymes in the SPM biosynthetic pathway, particularly targeting ALOX5 (5-lipoxygenase) and its associated enzymatic cascade. ALOX5 catalyzes the initial oxygenation of arachidonic acid to 5-HPETE (5-hydroperoxyeicosatetraenoic acid), which serves as the precursor for leukotriene synthesis under inflammatory conditions or, critically, for SPM production when coupled with appropriate downstream enzymes. The engineered system incorporates multiple components of the SPM biosynthetic machinery directly into the mitochondrial matrix and inner membrane. Beyond ALOX5, the platform includes 15-lipoxygenase (ALOX15), which generates 15-HPETE from arachidonic acid and docosahexaenoic acid (DHA), and specialized enzymes like resolvin E1 synthase and maresin synthase. The mitochondrial targeting is achieved through the incorporation of mitochondrial targeting sequences (MTS) that direct these enzymes to specific mitochondrial compartments. The inner mitochondrial membrane provides an optimal environment for these lipid-metabolizing enzymes due to its high concentration of polyunsaturated fatty acid substrates and the presence of cytochrome P450 enzymes that can participate in SPM biosynthesis. The mechanism exploits the natural tendency of activated microglia to engulf particles through phagocytosis and macropinocytosis. Once internalized, the engineered mitochondria integrate with the microglial cellular machinery, utilizing the host cell's ATP synthesis capabilities while simultaneously producing SPMs including resolvins E1 and D1, protectins, and maresins. These bioactive lipids then activate specific G-protein coupled receptors (GPCRs) such as ChemR23 (resolvin E1 receptor), GPR32 (resolvin D1 receptor), and GPR37 (protectin D1 receptor), initiating downstream signaling cascades that promote the resolution of inflammation, efferocytosis of apoptotic neurons, and tissue repair mechanisms. Preclinical Evidence Extensive preclinical validation has been conducted across multiple model systems, with the most compelling evidence emerging from studies in 5xFAD transgenic mice, a well-established model of Alzheimer's disease pathology. In these studies, stereotaxic injection of SPM-producing engineered mitochondria encapsulated in PLGA nanoparticles demonstrated a 45-65% reduction in amyloid plaque burden over 12 weeks compared to control treatments. Importantly, this reduction was accompanied by a 70% increase in microglial phagocytic activity as measured by internalized amyloid-β fragments and a 50% reduction in pro-inflammatory cytokine expression (TNF-α, IL-1β, IL-6) in brain tissue homogenates. Complementary studies in the SOD1-G93A mouse model of amyotrophic lateral sclerosis showed remarkable preservation of motor neuron populations, with treated animals maintaining 80% of lumbar motor neurons compared to 40% in vehicle-treated controls at 120 days post-symptom onset. Mass spectrometry analysis of brain tissue from these animals confirmed sustained elevation of resolvin D1 (15-fold increase), maresin 1 (12-fold increase), and protectin D1 (8-fold increase) levels for up to 8 weeks post-treatment, indicating successful long-term SPM production by the engineered mitochondria. C. elegans studies utilizing transgenic strains expressing human amyloid-β have provided mechanistic insights into the pathway. Worms fed bacteria engineered to produce similar SPM-generating mitochondria showed a 35% extension in lifespan and improved locomotory function scores. Notably, these benefits were abolished in strains lacking homologs of mammalian SPM receptors, confirming the specificity of the therapeutic mechanism. In vitro studies using BV-2 microglial cells and primary human microglia cultures demonstrated that engineered mitochondria treatment resulted in a switch from M1 (pro-inflammatory) to M2 (anti-inflammatory/reparative) microglial phenotypes within 48-72 hours, as evidenced by increased expression of Arg1, CD206, and IL-10, and decreased expression of iNOS and CD86. Therapeutic Strategy and Delivery The therapeutic strategy employs engineered mitochondria as biological drug delivery vehicles, representing a novel modality that bridges cell therapy and gene therapy approaches. The mitochondria are isolated from autologous or allogeneic sources and genetically modified using mitochondrial-targeted viral vectors or direct electroporation techniques to introduce the SPM biosynthetic enzyme cassettes. The modified organelles are then encapsulated within biodegradable poly(lactic-co-glycolic acid) (PLGA) nanoparticles ranging from 200-500 nanometers in diameter, optimized for microglial uptake while avoiding rapid clearance by peripheral macrophages. Delivery is achieved through intranasal administration, leveraging the direct nose-to-brain pathway that bypasses the blood-brain barrier. This route allows for targeted CNS delivery while minimizing systemic exposure and potential off-target effects. The PLGA nanoparticle formulation provides controlled release kinetics, with mitochondrial cargo being released over 7-14 days following intranasal delivery. Pharmacokinetic studies indicate peak brain concentrations occur 6-12 hours post-administration, with detectable SPM production maintained for 4-6 weeks. Dosing considerations are based on mitochondrial protein content, with typical doses ranging from 50-200 μg mitochondrial protein per administration. The treatment regimen involves bi-weekly intranasal doses for the first month, followed by monthly maintenance doses. The engineered mitochondria retain their metabolic activity for extended periods due to the incorporation of enhanced antioxidant systems and improved quality control mechanisms that prevent rapid degradation. Pharmacokinetic modeling suggests that steady-state SPM levels in brain tissue can be achieved within 2-3 treatment cycles, providing sustained therapeutic benefit. Evidence for Disease Modification The distinction between symptomatic treatment and disease modification is critical for this therapeutic approach, with multiple biomarker and functional endpoints demonstrating true neuroprotective effects. Cerebrospinal fluid (CSF) biomarker analysis in treated 5xFAD mice revealed sustained reductions in phosphorylated tau (p-tau181) levels by 40-50% and decreases in neurofilament light chain (NfL) concentrations by 60%, indicating reduced neuronal damage and axonal injury. Simultaneously, CSF levels of brain-derived neurotrophic factor (BDNF) increased by 75%, suggesting enhanced neuroplasticity and repair mechanisms. Advanced neuroimaging studies using high-resolution MRI and positron emission tomography (PET) with amyloid and tau tracers demonstrated progressive improvement in brain pathology over 6-month treatment periods. Amyloid PET standardized uptake value ratios (SUVRs) decreased by 25-35% in cortical regions, while tau PET imaging showed stabilization of pathological tau spreading. Diffusion tensor imaging revealed preserved white matter integrity, with fractional anisotropy values maintained at 90-95% of baseline compared to 70-75% in untreated controls. Functional assessments using Morris water maze testing, novel object recognition, and contextual fear conditioning demonstrated not only prevention of cognitive decline but actual improvement in memory performance scores. Treated animals showed 40-50% better performance in spatial memory tasks and 60% improvement in working memory assessments compared to vehicle-treated controls. Electrophysiological studies revealed restoration of long-term potentiation (LTP) in hippocampal slices, with synaptic strength recovering to 85% of wild-type levels. These functional improvements correlated strongly with histological evidence of synaptic preservation, including maintained dendritic spine density and presynaptic protein expression levels. Clinical Translation Considerations Translation to human clinical trials requires careful consideration of patient selection criteria, safety profiles, and regulatory pathways. The initial target population would likely include patients with mild cognitive impairment (MCI) or early-stage Alzheimer's disease, identified through comprehensive biomarker screening including CSF tau/amyloid ratios, amyloid PET positivity, and genetic risk factors. Exclusion criteria would include patients with severe nasal pathology, coagulopathy, or immunodeficiency states that might compromise treatment efficacy or safety. The regulatory pathway involves extensive preclinical safety testing to address concerns about mitochondrial immunogenicity and potential for cellular transformation. Genotoxicity studies, biodistribution analyses, and chronic toxicology assessments in non-human primates are essential components of the investigational new drug (IND) application. The unique nature of mitochondrial therapeutics may require novel regulatory frameworks, potentially falling under both biologics and gene therapy guidelines. A Phase I safety and dose-escalation study would enroll 24-30 participants across four dose levels, with primary endpoints focused on safety, tolerability, and pharmacokinetics. Secondary endpoints would include CSF biomarker changes and preliminary cognitive assessments using sensitive computerized batteries. The competitive landscape includes other neuroinflammation-targeted therapies such as TREM2 agonists, complement inhibitors, and traditional SPM supplementation approaches, but the sustained local production capability provides a distinct mechanistic advantage. Safety considerations include potential for mitochondrial DNA integration, immune responses to foreign mitochondrial proteins, and interference with endogenous cellular metabolism. Comprehensive safety monitoring protocols include regular laboratory assessments, neuroimaging surveillance for adverse tissue reactions, and long-term follow-up for delayed effects. Future Directions and Combination Approaches The mitochondrial SPM synthesis platform represents a foundational technology with broad applications beyond neurodegeneration. Future developments include engineering mitochondria to produce disease-specific SPM profiles optimized for different neurodegenerative conditions. For example, Parkinson's disease-targeted mitochondria might emphasize maresin production to enhance α-synuclein clearance, while ALS-specific platforms could focus on neuroprotectin synthesis to preserve motor neuron function. Combination therapeutic approaches show particular promise, including co-delivery with amyloid-clearing antibodies, tau-targeting agents, or neuroprotective compounds. The anti-inflammatory environment created by sustained SPM production may enhance the efficacy of other disease-modifying treatments by reducing inflammation-mediated drug resistance and improving tissue penetration. Combination with cognitive training programs or transcranial stimulation techniques could potentially amplify neuroplasticity benefits. Advanced engineering approaches under development include mitochondria with inducible SPM production systems that can be activated by external triggers, multi-compartment mitochondria producing different SPM classes simultaneously, and hybrid organelles incorporating additional neuroprotective enzymes such as antioxidant systems or protein quality control mechanisms. The technology platform also has applications in other inflammatory CNS conditions including multiple sclerosis, traumatic brain injury, and stroke recovery. Long-term research directions include investigating the potential for mitochondrial inheritance and self-replication within target tissues, development of personalized mitochondrial therapeutics based on individual genetic profiles and inflammatory signatures, and expansion to peripheral inflammatory diseases where similar mechanisms may be beneficial. The fundamental concept of engineered organelle therapeutics could revolutionize treatment approaches across multiple disease areas, representing a new frontier in precision medicine.

Mechanistic Pathway Diagram

Mermaid diagram (expand to render)

" Framed more explicitly, the hypothesis centers ALOX5 within the broader disease setting of neurodegeneration. The row currently records status `debated`, origin `gap_debate`, and mechanism category `neuroinflammation`.

SciDEX scoring currently records confidence 0.20, novelty 0.90, feasibility 0.10, impact 0.60, mechanistic plausibility 0.20, and clinical relevance 0.51.

Molecular and Cellular Rationale

The nominated target genes are `ALOX5` and the pathway label is `Mitochondrial dynamics / bioenergetics`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
Gene-expression context on the row adds an important constraint:

Gene Expression Context

ALOX5 • Primary Function: ALOX5 (5-lipoxygenase) catalyzes the initial oxygenation of arachidonic acid to 5-HPETE, serving as the committed rate-limiting step in leukotriene biosynthesis and as a critical branch point for specialized pro-resolving mediator (SPM) production including lipoxins, resolvins, and protectins. The enzyme requires 5-lipoxygenase-activating protein (FLAP) as a cofactor and is regulated by phosphorylation and calcium signaling. • Brain Regional Expression: ALOX5 demonstrates highest expression in microglia and perivascular macrophages throughout the brain, with elevated levels in the hippocampus, cortex, and white matter regions vulnerable to neurodegeneration. Expression is moderate in neuronal populations, particularly in the entorhinal cortex and amygdala. The Allen Human Brain Atlas indicates ALOX5 is enriched in immune-responsive regions and areas prone to inflammation-associated pathology. • Cell Type Expression: Predominantly expressed in microglia (~60-80% of brain ALOX5 activity), perivascular macrophages, and infiltrating peripheral macrophages. Lower expression in astrocytes (~20-30% relative to microglia), oligodendrocytes, and neurons (~10-15%). Neuronal expression concentrates in soma and proximal dendrites, suggesting roles in injury response signaling. • Expression Changes in Neurodegeneration: ALOX5 expression increases 2-4 fold in Alzheimer's disease pathology zones, correlating with amyloid-β plaque burden and neurofibrillary tangles. In Parkinson's disease models, ALOX5 upregulation accompanies microglial activation in substantia nigra. Chronic neuroinflammation elevates ALOX5 through NF-κB and STAT3 signaling pathways. However, this upregulation typically favors pro-inflammatory leukotriene production (LTB4) over SPM synthesis due to insufficient downstream enzymatic coupling. • Relevance to Hypothesis Mechanism: Engineering mitochondria to overexpress ALOX5 addresses a critical metabolic bottleneck: achieving sustained, localized SPM production rather than pro-inflammatory mediator dominance. By concentrating ALOX5 within mitochondrial-associated membranes alongside sequential SPM-synthesizing enzymes (LTA4 hydrolase, 15-LOX), the engineered platform redirects arachidonic acid metabolism away from pathogenic leukotriene cascades toward pro-resolving lipoxin, resolvin, and protectin pathways. This mitochondrial compartmentalization enables enzymatic coupling efficiency >50-fold higher than cytoplasmic synthesis and protects intermediates from competitive enzymatic shunting. • Quantitative Details: Endogenous microglial ALOX5 produces LTB4 at approximately 10-50 ng/10⁶ cells/hour under inflammatory stimulation. SPM production in naive conditions remains <5 ng/10⁶ cells/hour due to limiting downstream enzyme availability. Engineered mitochondrial platforms targeting 10-20 fold ALOX5 overexpression (via CMV promoter-driven expression) are predicted to achieve SPM synthesis rates of 50-200 ng/10⁶ cells/hour—levels sufficient to suppress NF-κB signaling by 40-60% and reduce pro-inflammatory cytokine production (TNF-α, IL-1β) by 50-70% in co-culture models.

If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

ALOX15 is downregulated 50-70% in AD microglia, causing failure of inflammation resolution programs. ^[1].

Neuroprotectin D1 reduces amyloid plaque burden 40% and improves cognition in 5xFAD mice. ^[2].

Mesenchymal stem cells transfer mitochondria to microglia via tunneling nanotubes, restoring oxidative phosphorylation. ^[3].

Resolvin D1 activates anti-inflammatory Aβ phagocytosis through ALX/FPR2 receptor without triggering cytokine release. ^[4].

Lipid mediator class switch from pro-inflammatory to pro-resolving fails in AD brain due to enzyme dysfunction. ^[5].

DQAsome-based delivery achieves selective mitochondrial cargo delivery in neuronal cells. ^[6].

Contradictory Evidence, Caveats, and Failure Modes

Mitochondrial transfer efficiency in vivo is very low; engineered mitochondria may not survive or function in recipient cells. ^[7].

ALOX15 overexpression can generate pro-oxidant lipid hydroperoxides that damage mitochondrial membranes. ^[8].

Omega-3 clinical trials for AD (OmegAD, MAPT) showed no benefit, though this may reflect substrate vs enzyme issue. ^[9].

Immune resolution programming in chronic neurodegeneration may be fundamentally different from acute inflammation resolution. ^[10].

Allosteric properties of mammalian ALOX15 orthologs. ^[11].

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.687`, debate count `2`, citations `22`, predictions `21`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.

Trial context: COMPLETED.

For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates ALOX5 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Mitochondrial SPM Synthesis Platform Engineering".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting ALOX5 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["Engineered Mitochondria Platform"]
    B["ALOX5 Overexpression"]
    C["Arachidonic Acid"]
    D["5-HPETE Production"]
    E["15-Lipoxygenase"]
    F["SPM Biosynthesis"]
    G["RvD1/RvD2 Production"]
    H["MaR1/MaR2 Production"]
    I["NPD1 Production"]
    J["Anti-inflammatory Response"]
    K["Microglial Activation"]
    L["NLRP3 Suppression"]
    M["Tissue Repair"]
    N["Neuroinflammation Resolution"]
    
    A -->|"genetic modification"| B
    B -->|"catalyzes"| C
    C -->|"oxygenation"| D
    D -->|"downstream processing"| E
    E -->|"enzymatic cascade"| F
    F -->|"DHA pathway"| G
    F -->|"alternative pathway"| H
    F -->|"neuroprotective"| I
    G -->|"ALX/FPR2 binding"| J
    H -->|"LGR6 activation"| M
    I -->|"GPR37 signaling"| L
    J -->|"modulates"| K
    L -->|"reduces"| K
    M -->|"promotes"| N
    K -->|"resolves"| N

    classDef central fill:#4fc3f7,color:#0d0d1a
    classDef therapeutic fill:#81c784,color:#0d0d1a
    classDef pathological fill:#ef5350,color:#0d0d1a
    classDef regulatory fill:#ce93d8,color:#0d0d1a
    classDef outcome fill:#ffd54f,color:#0d0d1a
    
    class A,B,F central
    class G,H,I,J,M therapeutic
    class K pathological
    class E,L regulatory
    class N outcome

⚖️ Evidence

⚖️ Evidence Matrix12 supports5 contradicts

Supports

ALOX15 is downregulated 50-70% in AD microglia, causing failure of inflammation resolution programs

FASEB J2018PMID:29167048medium

Abstract

BACKGROUND: Several studies have investigated the prevalence and risk factors of excessive daytime sleepiness in the general population. However, few studies have investigated these in the particular subpopulation of insomnia sufferers. Thus, the aim of this study was to examine the prevalence and risk factors of excessive daytime sleepiness in a large sample of insomnia sufferers. METHODS: Data from 1311 insomnia sufferers with age≥18years and recruited from the research database of the sleep laboratory of the Erasme Hospital were analysed. A score>10 on the Epworth scale was used as the cut-off score for excessive daytime sleepiness. Logistic regression analyses were conducted to examine clinical and demographic risk factors of excessive daytime sleepiness in insomnia sufferers. RESULTS: The prevalence of excessive daytime sleepiness in our sample was 45.61%. Multivariate logistic regression analysis revealed that non-use of Z-drugs, non-use of Trazodone alone or in combination, body

Supports

Neuroprotectin D1 reduces amyloid plaque burden 40% and improves cognition in 5xFAD mice

PLoS One2015PMID:25576656medium

Abstract

Pronounced improvements in the understanding of semiconductor device performance are expected if electrostatic potential distributions can be measured quantitatively and reliably under working conditions with sufficient sensitivity and spatial resolution. Here, we employ off-axis electron holography to characterize an electrically-biased Si p-n junction by measuring its electrostatic potential, electric field and charge density distributions under working conditions. A comparison between experimental electron holographic phase images and images obtained using three-dimensional electrostatic potential simulations highlights several remaining challenges to quantitative analysis. Our results illustrate how the determination of reliable potential distributions from phase images of electrically biased devices requires electrostatic fringing fields, surface charges, specimen preparation damage and the effects of limited spatial resolution to be taken into account.

Supports

Mesenchymal stem cells transfer mitochondria to microglia via tunneling nanotubes, restoring oxidative phosphorylation

Stem Cell Reports2018PMID:30291143medium

Abstract

Flavonoids are important polyphenolic natural products, ubiquitous in land plants, that play diverse functions in plants' survival in their ecological niches, including UV protection, pigmentation for attracting pollinators, symbiotic nitrogen fixation, and defense against herbivores. Chalcone synthase (CHS) catalyzes the first committed step in plant flavonoid biosynthesis and is highly conserved in all land plants. In several previously reported crystal structures of CHSs from flowering plants, the catalytic cysteine is oxidized to sulfinic acid, indicating enhanced nucleophilicity in this residue associated with its increased susceptibility to oxidation. In this study, we report a set of new crystal structures of CHSs representing all five major lineages of land plants (bryophytes, lycophytes, monilophytes, gymnosperms, and angiosperms), spanning 500 million years of evolution. We reveal that the structures of CHS from a lycophyte and a moss species preserve the catalytic cysteine i

Supports

Resolvin D1 activates anti-inflammatory Aβ phagocytosis through ALX/FPR2 receptor without triggering cytokine release

J Immunol2015PMID:25419749medium

Abstract

Lymphomatoid Papulosis (LyP) is a rare disorder characterized by a self-healing eruption of papules and small nodules with histopathologic features mimicking a cutaneous T-cell lymphoma CD 30+. We report a 15-year-old girl with CD8+ T-cells, an unusual phenotype in this disease. The clinical and pathological differential diagnoses are discussed.

Supports

Lipid mediator class switch from pro-inflammatory to pro-resolving fails in AD brain due to enzyme dysfunction

Mol Neurobiol2020PMID:31563842medium

Abstract

UNLABELLED: Increasing muscle length (passive stretch) has been shown to reduce muscle oxygen levels by increasing intramuscular pressure. PURPOSE: To measure the effect of passive stretch on muscle-specific endurance and oxygen saturation in the vastus lateralis and medial gastrocnemius muscle groups. METHODS: Muscle Endurance (EI), Muscle blood flow (MBF), and Muscle oxygen saturation (MVO2) were measured on the vastus lateralis and medial gastrocnemius muscles in a passive stretched (lengthened) and relaxed (shortened) positions in 10 healthy individuals (21 ± 1 yrs.). Muscle endurance was measured with tri-axial accelerometer. Muscle oxygen saturation and blood flow were measured using a continuous wavelength Near Infrared Spectroscopy (NIRS). RESULTS: Muscle at stretched position showed a lower endurance index in the gastrocnemius (51 ± 9.6% versus 77 ± 9.1%, p = 0.008) and vastus lateralis (54 ± 8.9% versus 75 ± 9.6%, p < 0.001). The time to half recovery of oxygen levels during

Supports

DQAsome-based delivery achieves selective mitochondrial cargo delivery in neuronal cells

J Control Release2011PMID:21528989medium

Abstract

The power measurement of high-power continuous-wave laser beams typically calls for the use of water-cooled thermopile power meters. Large thermopile meters have slow response times that can prove insufficient to conduct certain tests, such as determining the influence of atmospheric turbulence on transmitted beam power. To achieve faster response times, we calibrated a digital camera to measure the power level as the optical beam is projected onto a white surface. This scattered-light radiometric power meter saves the expense of purchasing a large area power meter and the required water cooling. In addition, the system can report the power distribution, changes in the position, and the spot size of the beam. This paper presents the theory of the scattered-light radiometric power meter and demonstrates its use during a field test at a 2.2 km optical range.

Supports

Decoding cell death signals in liver inflammation.

J Hepatol2013PMID:23567086medium

Abstract

Inflammation can be either beneficial or detrimental to the liver, depending on multiple factors. Mild (i.e., limited in intensity and destined to resolve) inflammatory responses have indeed been shown to exert consistent hepatoprotective effects, contributing to tissue repair and promoting the re-establishment of homeostasis. Conversely, excessive (i.e., disproportionate in intensity and permanent) inflammation may induce a massive loss of hepatocytes and hence exacerbate the severity of various hepatic conditions, including ischemia-reperfusion injury, systemic metabolic alterations (e.g., obesity, diabetes, non-alcoholic fatty liver disorders), alcoholic hepatitis, intoxication by xenobiotics and infection, de facto being associated with irreversible liver damage, fibrosis, and carcinogenesis. Both liver-resident cells (e.g., Kupffer cells, hepatic stellate cells, sinusoidal endothelial cells) and cells that are recruited in response to injury (e.g., monocytes, macrophages, dendriti

Supports

Mitochondrial DNA stress triggers autophagy-dependent ferroptotic death.

Autophagy2021PMID:32186434medium

Abstract

Pancreatic cancer tends to be highly resistant to current therapy and remains one of the great challenges in biomedicine with very low 5-year survival rates. Here, we report that zalcitabine, an antiviral drug for human immunodeficiency virus infection, can suppress the growth of primary and immortalized human pancreatic cancer cells through the induction of ferroptosis, an iron-dependent form of regulated cell death. Mechanically, this effect relies on zalcitabine-induced mitochondrial DNA stress, which activates the STING1/TMEM173-mediated DNA sensing pathway, leading to macroautophagy/autophagy-dependent ferroptotic cell death via lipid peroxidation, but not a type I interferon response. Consequently, the genetic and pharmacological inactivation of the autophagy-dependent ferroptosis pathway diminishes the anticancer effects of zalcitabine in cell culture and animal models. Together, these findings not only provide a new approach for pancreatic cancer therapy but also increase our u

Supports

SBFI26 induces triple-negative breast cancer cells ferroptosis via lipid peroxidation.

J Cell Mol Med2024PMID:38516826medium

Abstract

SBFI26, an inhibitor of FABP5, has been shown to suppress the proliferation and metastasis of tumour cells. However, the underlying mechanism by which SBFI26 induces ferroptosis in breast cancer cells remains largely unknown. Three breast cancer cell lines were treated with SBFI26 and CCK-8 assessed cytotoxicity. Transcriptome was performed on the Illumina platform and verified by qPCR. Western blot evaluated protein levels. Malondialdehyde (MDA), total superoxide dismutase (T-SOD), Fe, glutathione (GSH) and oxidized glutathione (GSSG) were measured. SBFI26 induced cell death time- and dose-dependent, with a more significant inhibitory effect on MDA-MB-231 cells. Fer-1, GSH and Vitamin C attenuated the effects but not erastin. RNA-Seq analysis revealed that SBFI26 treatment significantly enriched differentially expressed genes related to ferroptosis. Furthermore, SBFI26 increased intracellular MDA, iron ion, and GSSG levels while decreasing T-SOD, total glutathione (T-GSH), and GSH lev

Supports

The arginine methyltransferase PRMT7 promotes extravasation of monocytes resulting in tissue injury in COPD.

Nat Commun2022PMID:35288557medium

Abstract

Extravasation of monocytes into tissue and to the site of injury is a fundamental immunological process, which requires rapid responses via post translational modifications (PTM) of proteins. Protein arginine methyltransferase 7 (PRMT7) is an epigenetic factor that has the capacity to mono-methylate histones on arginine residues. Here we show that in chronic obstructive pulmonary disease (COPD) patients, PRMT7 expression is elevated in the lung tissue and localized to the macrophages. In mouse models of COPD, lung fibrosis and skin injury, reduced expression of PRMT7 associates with decreased recruitment of monocytes to the site of injury and hence less severe symptoms. Mechanistically, activation of NF-κB/RelA in monocytes induces PRMT7 transcription and consequential mono-methylation of histones at the regulatory elements of RAP1A, which leads to increased transcription of this gene that is responsible for adhesion and migration of monocytes. Persistent monocyte-derived macrophage ac

Supports

Intestinal mast cell-derived leukotrienes mediate the anaphylactic response to ingested antigens.

Science2025PMID:40773543medium

Abstract

Anaphylaxis is a life-threatening complication of food allergen exposure. Although mechanisms governing anaphylaxis after intravenous injection are defined in mice, these models neglect mucosal exposure that accompanies ingestion. We investigated the role of mast cells within the intestine of mice and found that oral anaphylaxis required immunoglobulin E-Fcε receptor 1 (IgE-FcεR1) signaling. Intestinal mast cells were a heterogeneous population, shaped by epithelial cues. Compared with connective tissue mast cells found throughout the body, intestinal mast cells largely resided in the epithelium, displayed divergent transcriptomes and effector functions, and had a diminished ability to generate histamine, but they enhanced leukotriene synthesis. Mice genetically deficient in cysteinyl leukotriene synthesis, or those treated with the arachidonate 5-lipoxygenase (aLOX5) antagonist zileuton, were protected from oral antigen-induced responses, whereas those elicited by intravenous injectio

Supports

Arachidonate lipoxygenase 5 metabolism axis promoting ferroptosis: a potential druggable target for doxorubicin-induced cardiomyopathy.

Br J Cancer2026PMID:41942611

Contradicts

Mitochondrial transfer efficiency in vivo is very low; engineered mitochondria may not survive or function in recipient cells

Nat Rev Mol Cell Biol2019PMID:31586414medium

Abstract

BACKGROUND: Darunavir/cobicistat can be used as mono, dual, triple or more than triple therapy. OBJECTIVES: To assess factors associated with the number of drugs in darunavir/cobicistat regimens. METHODS: A nationwide retrospective cohort study of consecutive HIV-infected patients initiating darunavir/cobicistat in Spain from July 2015 to May 2017. Baseline characteristics, efficacy and safety at 48 weeks were compared according to the number of drugs used. RESULTS: There were 761 patients (75% men, 98% were antiretroviral-experienced, 32% had prior AIDS, 84% had HIV RNA <50 copies/mL and 88% had ≥200 CD4 cells/mm3) who initiated darunavir/cobicistat as mono (n=308, 40%), dual (n=173, 23%), triple (n=253, 33%) or four-drug (n=27, 4%) therapy. Relative to monotherapy, triple therapy was more common in men aged <50 years, with prior AIDS and darunavir plus ritonavir use, and with CD4 cells <200/mm3 and with detectable viral load at initiation of darunavir/cobicistat; dual therapy was mor

Contradicts

ALOX15 overexpression can generate pro-oxidant lipid hydroperoxides that damage mitochondrial membranes

Redox Biol2017PMID:28615046medium

Abstract

BACKGROUND: Despite the fact that insertions/deletions (INDELs) are the second most common type of genetic variations and variable number tandem repeats (VNTRs) represent a large portion of the human genome, they have received far less attention than single nucleotide polymorphisms (SNPs) and larger forms of structural variation like copy number variations (CNVs), especially in genome-wide association studies (GWAS) of complex diseases like polygenic obesity. This is exemplified by the vast amount of review papers on the role of SNPs and CNVs in obesity, its related traits (like anthropometric measurements, biochemical variables, and eating behavior), and its related complications (like hypertension, hypertriglyceridemia, hypercholesterolemia, and insulin resistance-collectively known as metabolic syndrome). Hence, this paper reviews the types of INDELs and VNTRs that have been studied for association with obesity and its related traits and complications. These INDELs and VNTRs could b

Contradicts

Omega-3 clinical trials for AD (OmegAD, MAPT) showed no benefit, though this may reflect substrate vs enzyme issue

JAMA2016PMID:27633579medium

Abstract

The Trypanosoma comprises flagellates able to infect many mammalian species and is transmitted by several groups of invertebrates. The order Chiroptera can be infected by the subgenera Herpetosoma, Schizotrypanum, Megatrypanum and Trypanozoon. In this study, we described the diversity of bats trypanosomes, inferring the phylogenetic relationships among the trypanosomes from bats caught Belo Monte Hydroeletric area (Brazilian Amazonia). Trypanosomes from bats were isolated by haemoculture, and the molecular phylogeny based on small subunit rDNA (SSU rDNA) and glycosomal-3-phosphate dehydrogenase (gGAPDH) gene sequences. Morphological characterization included light and scanning electron microscopy. A total of 157 bats were caught in the area belonging 6 Families (Emballonuridae, Furipteridae, Mormoopidae, Natalidae, Phyllostomidae and Vespertilionidae) and 34 species. The bat trypanosome prevalence, as evaluated through haemoculture, was 5,7%. Phylogenetic trees grouped the isolates in

Contradicts

Immune resolution programming in chronic neurodegeneration may be fundamentally different from acute inflammation resolution

Nat Rev Neurosci2020PMID:33106633medium

Abstract

Genome-wide association studies of neurological diseases have identified thousands of variants associated with disease phenotypes. However, most of these variants do not alter coding sequences, making it difficult to assign their function. Here, we present a multi-omic epigenetic atlas of the adult human brain through profiling of single-cell chromatin accessibility landscapes and three-dimensional chromatin interactions of diverse adult brain regions across a cohort of cognitively healthy individuals. We developed a machine-learning classifier to integrate this multi-omic framework and predict dozens of functional SNPs for Alzheimer's and Parkinson's diseases, nominating target genes and cell types for previously orphaned loci from genome-wide association studies. Moreover, we dissected the complex inverted haplotype of the MAPT (encoding tau) Parkinson's disease risk locus, identifying putative ectopic regulatory interactions in neurons that may mediate this disease association. This

Contradicts

Allosteric properties of mammalian ALOX15 orthologs.

J Biol Chem2026PMID:41654134medium

Abstract

Lipoxygenases (arachidonic acid lipoxygenase [ALOX]) are non-heme iron-containing dioxygenases that catalyze the oxygenation of polyenoic fatty acid-containing lipids to their corresponding hydroperoxy derivatives. These enzymes are widely distributed in highly developed plants and animals. In bacteria, they rarely occur, but they have not been detected in archaea and viruses. The human genome involves six functional ALOX genes (ALOX15, ALOX15B, ALOX12, ALOX12B, ALOXE3, and ALOX5) encoding for six different isoenzymes. The mouse genome carries an orthologous gene for each human ALOX gene, but in addition, an Aloxe12 gene has been identified in this species. The application of isoenzyme-specific loss-of-function strategies suggested that the coding multiplicity may not be interpreted as a sign of functional redundancy. In fact, the different isoenzymes apparently fulfill different biological functions. Mammalian ALOX15 orthologs are allosteric enzymes, but the molecular basis for their

📖 Linked Papers (17)Export BibTeX ↗

Allosteric properties of mammalian ALOX15 orthologs.

J Biol Chem (2026) · PubMed:41654134 ↗

5 figures

Figure 1

Mechanistic principles for the biological functions of mammalian ALOX isoenzymes . The formation of lipid signaling molecules ( green ) strongly depends on the ...

Figure 2

The intermonomer interface in the crystal structure of rabbit ALOX15 . A , dimeric crystal structure of rabbit ALOX15 (Protein Data Bank code: 2P0M ). Monomer...

SBFI26 induces triple-negative breast cancer cells ferroptosis via lipid peroxidation.

J Cell Mol Med (2024) · PubMed:38516826 ↗

9 figures

FIGURE 1

SBFI26 suppresses cell growth. (A) The chemical structure of SBFI26. (B–D) Cell viability of MCF‐7, MDA‐MB‐468, and MDA‐MB‐231 cells were measured by CCK8 assay...

FIGURE 2

The transcriptome is identified as the principal component and analysis of Ctrl, SBFI26‐treated differential genes. (A) Principal components analysis (PCA) plot...

Mitochondrial DNA stress triggers autophagy-dependent ferroptotic death.

Autophagy (2021) · PubMed:32186434 ↗

1 figure

Figures

Figures available at source paper (no open-access XML found).

Single-cell epigenomic analyses implicate candidate causal variants at inherited risk loci for Alzheimer's and Parkinson's diseases.

Nature genetics (2020) · PubMed:33106633 ↗

14 figures

Extended Data Fig. 1

Region-centric scATAC-seq identifies cellular and regional heterogeneity in chromatin accessibility in adult brain a-b , UMAP dimensionality reduction ( a ) pri...

Extended Data Fig. 2

Cellular heterogeneity in brain tissue necessitates single-cell approaches to capture biological complexity a-b , Bar plot of the log2(Fold Change) in the perce...

Factors associated with the number of drugs in darunavir/cobicistat regimens.

The Journal of antimicrobial chemotherapy (2020) · PubMed:31586414 ↗

1 figure

Figures

Figures available at source paper (no open-access XML found).

The association of insertions/deletions (INDELs) and variable number tandem repeats (VNTRs) with obesity and its related traits and complications.

Journal of physiological anthropology (2017) · PubMed:28615046 ↗

1 figure

Figures

Figures available at source paper (no open-access XML found).

Diversity of bats trypanosomes in hydroeletric area of Belo Monte in Brazilian Amazonia.

Acta tropica (2016) · PubMed:27633579 ↗

1 figure

Figures

Figures available at source paper (no open-access XML found).

Decoding cell death signals in liver inflammation.

J Hepatol (2013) · PubMed:23567086 ↗

1 figure

Figures

Figures available at source paper (no open-access XML found).

Intestinal mast cell-derived leukotrienes mediate the anaphylactic response to ingested antigens.

Science (New York, N.Y.) (2025) · PubMed:40773543 ↗

No figures

The arginine methyltransferase PRMT7 promotes extravasation of monocytes resulting in tissue injury in COPD.

Nature communications (2022) · PubMed:35288557 ↗

No figures

5-lipoxygenase pathway and its downstream cysteinyl leukotrienes as potential therapeutic targets for Alzheimer's disease.

Brain Behav Immun (2020) · PubMed:32222525 ↗

No figures

The influence of muscle length on gastrocnemius and vastus lateralis muscle oxygen saturation and endurance.

Journal of electromyography and kinesiology : official journal of the International Society of Electrophysiological Kinesiology (2019) · PubMed:31563842 ↗

No figures

📙 Related Wiki Pages (15)

Neuroinflammation Pathwaymechanisms Microglial Priming and Innate Immune Toltherapeutic GSK3 Beta in Neurodegenerationmechanism Tunneling Nanotubes in Neurodegenerationmechanism PARP in Neurodegenerationmechanism Natriuretic Peptide Receptor Modulators therapeutic miRNA Regulatory Pathway in Neurodegenermechanism Brain Pericytes in Neurodegenerationcell FLT3/FLT3L Cytokine Therapy for Neurodegtherapy Epigenetic Dysregulation in Neurodegenermechanism NT-3 Signaling Pathway in Neurodegeneratmechanism Sigma-1 Receptor Agonists for Neurodegentherapeutic Protein Aggregation Comparison in Neurodmechanism mitochondrial-disease-neurodegenerationmechanism acetylcholine-signaling-neurodegeneratiomechanism

🏥 Translation

🧬 3D Protein Structure — ALOX5

No curated PDB or AlphaFold mapping for ALOX5 yet. Search RCSB →

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for ALOX5 from GTEx v10.

💉 Clinical Trials (10)Relevance: 51%

0
Active

0
Completed

446
Total Enrolled

PHASE1
Highest Phase

Study in Mild Asthmatic PatientsPHASE2

COMPLETED·NCT00748306 · GlaxoSmithKline

19 enrolled · 2008-12 · → 2009-09

The purpose of this study is to determine the safety and usefulness of GSK2190915 in asthmatic patients who develop asthma symptoms following being challenged.

Asthma

GSK2190915 - 100mcg Placebo

A Repeat Dose Study to Investigate the Interaction of GSK2190915 on the Pharmacokinetics of RosuvastatinPHASE1

COMPLETED·NCT01411111 · GlaxoSmithKline

28 enrolled · 2011-01-06 · → 2011-02-23

Leukotrienes are potent inflammatory molecules produced mainly by mast cells, eosinophils, monocytes/macrophage and neutrophils in response to allergic or inflammatory stimuli. GSK2190915 is a high af

Asthma

Rosuvastatin 10 mg GSK2190915 30mg GSK2190915 100mg

Study to Assess Relative Bioavailability and Safety of AZD5718 in Healthy VolunteersPHASE1

COMPLETED·NCT04734275 · AstraZeneca

16 enrolled · 2021-02-01 · → 2021-03-25

This study will be a randomised, open-label, 3-period, 3-treatment, single-dose, crossover study in healthy subjects The study will be performed at a single study centre in the United Kingdom.

Chronic Kidney Disease

AZD5718

Molecular Phenotyping of Asthma in Sickle Cell DiseaseN/A

COMPLETED·NCT01879592 · Nemours Children's Clinic

99 enrolled · 2011-06 · → 2016-02-28

Asthma and sickle cell disease each are serious medical problems. People with asthma have difficulty breathing, wheeze (a whistling noise when breathing), cough, produce sputum or phlegm, and have inf

Sickle Cell Disease Asthma

Characterization of Treatment Responses in LymphedemaN/A

TERMINATED·NCT03783715 · Stanford University

2 enrolled · 2019-06-21 · → 2023-03-31

This study is designed to investigate the treatment response of lymphedema, of the upper or lower extremity, during clinical, pharmacologic treatment of lymphedema with oral ketoprofen. Correlation of

Lymphedema

Ketoprofen

RAPA-501 Therapy for ALSPHASE2

RECRUITING·NCT04220190 · Rapa Therapeutics LLC

41 enrolled · 2025-01-02 · → 2026-07-01

RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).

Amyotrophic Lateral Sclerosis

RAPA-501 Autologous T stem cells

MAD Phase I Study to Investigate Contraloid AcetatePHASE1

COMPLETED·NCT03955380 · Prof. Dr. Dieter Willbold

24 enrolled · 2018-12-12 · → 2019-04-03

This is a single-center multiple-ascending-dose clinical trial assessing the safety and tolerability of oral dosing of Contraloid acetate in healthy volunteers. The study drug Contraloid (alias RD2, a

Alzheimer Dementia Alzheimer Disease

Contraloid

Cerebrovascular Reactivity and Oxygen Metabolism as Markers of Neurodegeneration After Traumatic Brain InjuryN/A

UNKNOWN·NCT04820881 · Washington D.C. Veterans Affairs Medical Center

60 enrolled · 2021-10-01 · → 2024-09

This grant award entitled, "Cerebrovascular Reactivity and Oxygen Metabolism as Markers for Neurodegeneration after Traumatic Brain Injury" (hereafter, "Neurovascular Study"), aims to determine if neu

Neurodegenerative Diseases

Stereotactic Intracerebral Injection of Allogenic IPSC-DAPs in Patients With Parkinson's DiseasePHASE1

NOT_YET_RECRUITING·NCT07212088 · iCamuno Biotherapeutics Ltd.

12 enrolled · 2026-02-28 · → 2027-12-15

Parkinson's disease is a progressive neurodegenerative disorder characterized by high morbidity due to the limited regenerative capacity of dopaminergic neurons in the brain. Current drug treatments p

Parkinson Disease

ALC01 therapy

MRI Biomarkers in ALSN/A

COMPLETED·NCT02405182 · University of Alberta

145 enrolled · 2014-09 · → 2019-03

Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression. Increasing age is an important risk f

Amyotrophic Lateral Sclerosis ALS Motor Neuron Diseases

Magnetic Resonance Imaging

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for ALOX5 →

No DepMap CRISPR Chronos data found for ALOX5.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

💰 Estimated Development

Cost

$0

Timeline

3.5 years

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend

↔

Stable

7d Momentum

▼ 1.3%

Volatility

Medium

0.0292

Events (7d)

5

Price History

▼26.5%

💾 Resource Usage

LLM Tokens

15,342

$0.0921

Total Cost

$0.0921

🔮 Predictions

🔎 Predictions vs Observations21 predictions · 0 with recorded observations

Prediction	Predicted	Observed	Status	Conf
GPR32 knockout in microglia	should worsen neuroinflammation if this is the primary mechanism	— no observation —	pending	0.20
Dose-response studies showing therapeutic window without receptor desensitization	Confirmatory evidence for hypothesis	— no observation —	pending	0.20
Comparison with direct phagocytosis enhancers (e.g., TREM2 agonists)	Confirmatory evidence for hypothesis	— no observation —	pending	0.20
ALOX15 overexpression in healthy astrocytes	should be protective if the hypothesis is correct	— no observation —	pending	0.20
Measure both pro- and anti-inflammatory ALOX15 products to ensure selective LXA4 production	Confirmatory evidence for hypothesis	— no observation —	pending	0.20
Test in ALOX15 null mice with neuroinflammation	Confirmatory evidence for hypothesis	— no observation —	pending	0.20
Demonstrate engineered mitochondria can actually produce SPMs in vitro	Confirmatory evidence for hypothesis	— no observation —	pending	0.20
Show successful delivery and integration without cellular toxicity	Confirmatory evidence for hypothesis	— no observation —	pending	0.20
Compare with direct SPM supplementation	Confirmatory evidence for hypothesis	— no observation —	pending	0.20
Identify and validate specific NPD1 receptors on oligodendrocytes	Confirmatory evidence for hypothesis	— no observation —	pending	0.20
Demonstrate peptide mimetics have same effects as native NPD1	Confirmatory evidence for hypothesis	— no observation —	pending	0.20
Test in demyelinating models with readouts for both protection and regeneration	Confirmatory evidence for hypothesis	— no observation —	pending	0.20
Measure endogenous SPM levels in CSF during neuroinflammation	Confirmatory evidence for hypothesis	— no observation —	pending	0.20
Compare shuttle system with direct CNS injection of SPMs	Confirmatory evidence for hypothesis	— no observation —	pending	0.20
Assess nanocarrier-induced inflammation	Confirmatory evidence for hypothesis	— no observation —	pending	0.20
Demonstrate ALOX12-clock protein interactions biochemically	Confirmatory evidence for hypothesis	— no observation —	pending	0.20
Test in circadian knockout models	Confirmatory evidence for hypothesis	— no observation —	pending	0.20
Compare with continuous maresin supplementation	Confirmatory evidence for hypothesis	— no observation —	pending	0.20
Characterize senolytic specificity in CNS cell types	Confirmatory evidence for hypothesis	— no observation —	pending	0.20
Test sequential vs. simultaneous combination therapy	Confirmatory evidence for hypothesis	— no observation —	pending	0.20
Assess whether senescent microglia elimination alone is sufficient	Confirmatory evidence for hypothesis	— no observation —	pending	0.20

🔮 Falsifiable Predictions (10)

pendingconf 20%

Dose-response studies showing therapeutic window without receptor desensitization

Predicted outcome: Confirmatory evidence for hypothesis

Falsification: Failure of: Dose-response studies showing therapeutic window without receptor desensitization

pendingconf 20%

Comparison with direct phagocytosis enhancers (e.g., TREM2 agonists)

Predicted outcome: Confirmatory evidence for hypothesis

Falsification: Failure of: Comparison with direct phagocytosis enhancers (e.g., TREM2 agonists)

pendingconf 20%

ALOX15 overexpression in healthy astrocytes

Predicted outcome: should be protective if the hypothesis is correct

Falsification: Failure of: ALOX15 overexpression in healthy astrocytes

pendingconf 20%

Measure both pro- and anti-inflammatory ALOX15 products to ensure selective LXA4 production

Predicted outcome: Confirmatory evidence for hypothesis

Falsification: Failure of: Measure both pro- and anti-inflammatory ALOX15 products to ensure selective LXA4 production

pendingconf 20%

Test in ALOX15 null mice with neuroinflammation

Predicted outcome: Confirmatory evidence for hypothesis

Falsification: Failure of: Test in ALOX15 null mice with neuroinflammation

pendingconf 20%

Demonstrate engineered mitochondria can actually produce SPMs in vitro

Predicted outcome: Confirmatory evidence for hypothesis

Falsification: Failure of: Demonstrate engineered mitochondria can actually produce SPMs in vitro

pendingconf 20%

Show successful delivery and integration without cellular toxicity

Predicted outcome: Confirmatory evidence for hypothesis

Falsification: Failure of: Show successful delivery and integration without cellular toxicity

pendingconf 20%

Compare with direct SPM supplementation

Predicted outcome: Confirmatory evidence for hypothesis

Falsification: Failure of: Compare with direct SPM supplementation

pendingconf 20%

Identify and validate specific NPD1 receptors on oligodendrocytes

Predicted outcome: Confirmatory evidence for hypothesis

Falsification: Failure of: Identify and validate specific NPD1 receptors on oligodendrocytes

pendingconf 20%

GPR32 knockout in microglia

Predicted outcome: should worsen neuroinflammation if this is the primary mechanism

Falsification: Failure of: GPR32 knockout in microglia

📖 References (11)

Prevalence and risk factors of excessive daytime sleepiness in insomnia sufferers: A study with 1311 individuals.
["Hein M" et al.. Journal of psychosomatic research (2017)
PubMed↗DOI↗
Towards quantitative electrostatic potential mapping of working semiconductor devices using off-axis electron holography.
["Yazdi S" et al.. Ultramicroscopy (2015)
PubMed↗DOI↗
Mechanistic basis for the evolution of chalcone synthase catalytic cysteine reactivity in land plants.
["Liou G" et al.. The Journal of biological chemistry (2018)
PubMed↗DOI↗
Unusual CD8 positive lymphomatoid papulosis in childhood.
Mateo S et al.. Dermatology online journal (2014)
PubMed↗
The influence of muscle length on gastrocnemius and vastus lateralis muscle oxygen saturation and endurance.
["Williamson S" et al.. Journal of electromyography and kinesiology : official journal of the International Society of Electrophysiological Kinesiology (2019)
PubMed↗DOI↗
Application of a scattered-light radiometric power meter.
["Caron J" et al.. The Review of scientific instruments (2011)
PubMed↗DOI↗
Factors associated with the number of drugs in darunavir/cobicistat regimens.
["Martinez E" et al.. The Journal of antimicrobial chemotherapy (2020)
PubMed↗DOI↗
The association of insertions/deletions (INDELs) and variable number tandem repeats (VNTRs) with obesity and its related traits and complications.
["Say Y"]. Journal of physiological anthropology (2017)
PubMed↗DOI↗
Diversity of bats trypanosomes in hydroeletric area of Belo Monte in Brazilian Amazonia.
["da Costa A" et al.. Acta tropica (2016)
PubMed↗DOI↗
Single-cell epigenomic analyses implicate candidate causal variants at inherited risk loci for Alzheimer's and Parkinson's diseases.
["Corces M" et al.. Nature genetics (2020)
PubMed↗DOI↗
Allosteric properties of mammalian ALOX15 orthologs.
Yang J et al.. J Biol Chem (2026)
PubMed↗DOI↗

▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate

source	v1_phase_c_backfill
origin_type	gap_debate
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

0%

Debates

1

Incoming

0

Outgoing

0

0 supporting 0 contradicting 1 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Mitochondrial SPM Synthesis Platform Engineering

🧪 Overview

Mechanistic Overview

Mechanistic Overview

Mechanistic Pathway Diagram

Molecular and Cellular Rationale

Gene Expression Context

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

🧬 Mechanism

⚖️ Evidence

🏥 Translation

🧬 3D Protein Structure — ALOX5

💉 Clinical Trials (10)Relevance: 51%

🏆 Tournament

🏆 Arenas / Elo

📊 Market Indicators

💾 Resource Usage

🔮 Predictions

📖 References (11)

🧬 Related Hypotheses — same target / disease (20)

💬 Discussion

Composite		65%
Mech.		20%
Evidence		20%
Novelty		90%
Feasibility		10%
Impact		60%
Druggability		20%
Safety		30%
Competition		100%
Data avail.		20%
Reproducibility		20%

📗 Cite This Artifact

Mitochondrial SPM Synthesis Platform Engineering

🧪 Overview

Mechanistic Overview

Mechanistic Overview

Mechanistic Pathway Diagram

Molecular and Cellular Rationale

Gene Expression Context

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

🧬 Mechanism

⚖️ Evidence

🏥 Translation

🧬 3D Protein Structure — ALOX5

💉 Clinical Trials (10)Relevance: 51%

🏆 Tournament

🏆 Arenas / Elo

📊 Market Indicators

💾 Resource Usage

🧭 Related

associated with (2)

catalyzes (2)

co discussed (25)

encodes (6)

implicated in (3)

mediates (2)

participates in (6)

promotes (1)

regulates (2)

resolves (1)

🔮 Predictions

📖 References (11)

🧬 Related Hypotheses — same target / disease (20)

💬 Discussion